President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message

The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.

President Bio-den
• Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The Biden Administration is launching a new National Biotechnology & Biomanufacturing Initiative designed to encourage investment in biotechnology via an executive order signed by the President on 12 September.

“This initiative will grow the strength and diversity of domestic biomanufacturing capacity, expand market opportunities for bio-based products through the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance